Figure 3.

FG Treatment Induces Mφ Infiltration in Tumors and Inhibits Tumor Growth through Mφs

(A–C) Quantification of tumor-infiltrating (A) CD45⁺ (n = 12–13), (B) CD11b⁺F4/80⁺ (n = 8), and (C) CD4⁺ and CD8⁺ (n = 5) cell ratios in LLC tumors by flow cytometric analysis.

(D) IF imaging of F4/80 (red)-stained sections of LLC tumors. Scale bar, 50 μm.

(E) Quantification of F4/80⁺ cell number per mm² of tumors (n = 5).

(F−I) Flow cytometric quantification of (F) Ly6C^hi, Ly6C^lo, and Ly6C^neg Mφ ratios in LLC tumors (n = 6), (G) the ratio of tumor-infiltrating CD11b⁺F4/80⁺ cells/CD45⁺ cells in B16F10 tumors (n = 4), (H) Ly6C^hi, Ly6C^lo, and Ly6C^neg Mφs ratios in B16F10 tumors (n = 4), and (I) CD4+ and CD8+ cell lymphocyte ratios in B16F10 tumors (n = 4).

(J) Tumor growth curves of the LLC tumor mouse model treated with liposome control or clodronate liposome and vehicle or 3 mg FG (relative to vehicle liposome controls; n = 4).

(K) IF images of F4/80 (red)-stained sections of LLC tumors. Scale bar, 50 μm.

(L) Quantification of F4/80⁺ cell number per mm² of tumors (n = 3).

Data represent means ±SEM. Mann-Whitney test (A–C and E–I); two-way ANOVA (J); unpaired Student's t test (L). ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. See also Figure S3.